设为首页收藏本站
开启辅助访问
切换到窄版

 找回密码
 注册

QQ登录

只需一步,快速开始

搜索
查看: 431|回复: 0

联合使用pomalidomide和CAR-T细胞对抗多发性骨髓瘤细胞RPMI8226和U266细胞

[复制链接]
发表于 2016-1-25 13:09:12 | 显示全部楼层 |阅读模式
Cytotoxity of pomalidomide combined CAR-T cell for multiple myeloma cell RPMI8226 and U266

OBJECTIVE:
To observe the cytotoxity of CD138-CAR-T cells on human multiple myeloma cell RPMI8226 and U266 cells and explore the impact of pomalidomide on the cytotoxity of CD138-CAR-T on RPMI8226 and U266 cells.
METHODS:
The cytotoxity of CD138-CAR-T and CD138-CAR-T combined pomalidomide on RPMI8226 and U266 was detected by CFSE/7AAD. The effctor cells were co-cultured with target cells at 5:1 for 18 h, and then the supernatant were collected and used for ELISA assays.
RESULTS:
After 18 h co-culture, the cytotoxity of CD138-CAR-T on RPMI8226 and U266 was significantiy higher than control (P<0.01). There was no significant change on the cytotoxity of pomalidoide combined with CD138-CAR-T on RPMI8226 and U266. The results showed that co-cultured system contribted to a markedly increased production of IFN-γ, after adding pomalidomide to the co-cultured system. It can significantly enhance the production of IFN-γ, compared with CD138-CAR-T alone.
CONCLUSION:
CD138-CAR-T had significantly cytotoxity on U266 and RPMI8226. Pomalidomide could promote CD138-CAR-T cells IFN-γ production.

联合使用pomalidomide和CAR-T细胞对抗多发性骨髓瘤细胞RPMI8226和U266细胞
目标:
为了观察CD 138-CAR-T细胞对人多发性骨髓瘤RPMI8226 和 U266细胞的毒性,以及探索联合使用pomalidomide和CAR-T细胞对多发性骨髓瘤细胞RPMI8226和U266细胞的作用。
方法:
CD138-CAR-T,CD138-CAR-T联合pomalidomide对多发性骨髓瘤RPMI8226和U266细胞的毒性通过CFSE/7AAD方法检测。效应细胞和靶细胞以5:1的比例共同培养18h,然后收集悬浮的细胞并做ELSA检测。
结果:
18h的共培养之后,CD138-CAR-T对多发性骨髓瘤RPMI8226和U266细胞的毒性明显高于控制组(P<0.01)。对于CD138-CAR-T联合pomalidomide这一组,对多发性骨髓瘤RPMI8226和U266细胞的毒性没有明显的变化。结果显示,在增加pomalidomide到该系统中,共培养系统会明显增加IFN-γ的量。与单独使用CD138-CAR-T相比,能够明显增加IFN-γ的量。
结论:
CD138-CAR-T能够明显增加对多发性骨髓瘤RPMI8226和U266细胞的毒性。Pomalidomide能够增加CD138-CAR-T细胞IFN-γ的生产。
出自爱康得生物技术
您需要登录后才可以回帖 登录 | 注册

本版积分规则

QQ|申请友链|小黑屋|手机版|Archiver|生物信息学论坛 ( 蜀ICP备09031721号  

GMT+8, 2017-2-19 22:48 , Processed in 0.092047 second(s), 22 queries .

Powered by Discuz! X3

© 2001-2013 Comsenz Inc.

快速回复 返回顶部 返回列表